Drug General Information (ID: DDI3PH05AW)
  Drug Name Adenosine Drug Info Doxepin (topical) Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Antiarrhythmic Agents Antidepressants
  Structure

 Mechanism of Adenosine-Doxepin (topical) Interaction (Severity Level: Moderate)
     Increased risk of ventricular arrhythmias Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Adenosine Doxepin (topical)
      Mechanism 1 Bradycardia Prolong QT interval
      Key Mechanism Factor 1
Factor Name Ventricular arrhythmias
Factor Description Ventricular arrhythmias are abnormal heart rhythms that cause your heart's lower chambers to pump blood instead of pumping it. This can limit or stop your heart from supplying blood to your body. While some of these arrhythmias are harmless and do not cause symptoms, others can have serious, even fatal, effects on your body.
      Mechanism Description
  • Increased risk of ventricular arrhythmias by the combination of Adenosine and Doxepin (topical) 
      Mechanism 2 Delay atrioventricular conduction Prolong QT interval
      Key Mechanism Factor 2
Factor Name Ventricular arrhythmias
Factor Description Ventricular arrhythmias are abnormal heart rhythms that cause your heart's lower chambers to pump blood instead of pumping it. This can limit or stop your heart from supplying blood to your body. While some of these arrhythmias are harmless and do not cause symptoms, others can have serious, even fatal, effects on your body.
      Mechanism Description
  • Increased risk of ventricular arrhythmias by the combination of Adenosine and Doxepin (topical) 

Recommended Action
      Management Adenosine should be used with caution in patients receiving drugs that may prolong the QT interval. Adenosine should be discontinued immediately if severe bradycardia occurs.

References
1 Mallet ML "Proarrhythmic effects of adenosine: a review of the literature." Emerg Med J 21 (2004): 408-10. [PMID: 15208219]
2 Michalets EL, Williams CR "Drug interactions with cisapride: clinical implications." Clin Pharmacokinet 39 (2000): 49-75. [PMID: 10926350]
3 Wesley RC Jr, Turnquest P "Torsades de pointe after intravenous adenosine in the presence of prolonged QT syndrome." Am Heart J 123 (1992): 794-6. [PMID: 1539535]